And you all by now know its stock is up almost 800% this year alone. Here's the latest -- in any event, on all that -- with very promising remarks, from CEO Bancel:
. . .Following a series of industry-defining readouts for its personalised cancer vaccine intismeran autogene, Moderna is eyeing a future bigger than one of oncology’s stalwart therapies.
“Over time, it could actually be bigger than Keytruda”, Stéphane Bancel, CEO of Moderna, said in a keynote interview at the Financial Times Global Pharma and Biotech Summit on 10 November.
“The reason is the following – we are going to try it everywhere Keytruda works. We believe that when you add intismeran to Keytruda, you have a better clinical outcome,” he added. . . .
Bancel highlighted intismeran’s beneficial safety profile over current checkpoint inhibitors, for which long-term toxicity can be an issue. There is also the potential to combine intismeran with other drugs in cancers where Keytruda is not as effective. . . .
Still a long road to final FDA approvals, in various specific cancers -- but very promising, indeed -- for people who face the often-daunting diagnosis -- of one or more solid organ tumors / cancers.
Separately, I should mention that the morons Trump has appointed are now "suspending" the interim regs allowing for "Commissioners National" priority vouchers at FDA. Damn -- not sure what newly-revised grift this latest move allows, but you can bet that is what is behind this (again) scientifically-dubious move. Out.
नमस्ते
No comments:
Post a Comment